Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 359

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 359
---
, and comprehensive artificial intelligence analysis to further develop our current and future products. In addition to using AI for data interpretation and processing, we plan to develop AI Agents designed to interact directly with customers. We expect that AI Agents will play a role in providing personalized health guidance, interpreting results, and supporting telemedicine services, allowing us to scale our offerings. Furthermore, we value the use of technology breakthroughs and advancements in self and remote testing, as we plan on collecting complete omni -modaldata to accelerate our innovations, improve localized results and develop future products. 177 • Customer experience: we view customer experience for patients, physicians, healthcare providers, and partners as a fundamental element of our long -termgrowth strategy and a powerful tool to facilitate the integration of genetics into mainstream medicine. We believe that providing excellent products and ensuring “ease -of-use,” such as onboarding, streamlined ordering, results interpretation and fast turnaround times, are key for all our customers. As such, our products and services are developed based on user insights, local languages and cultures, operations and logistics requirements, and unmet market needs that we have identified. We have a track record that has allowed us to achieve product market fit with our services. As such, we believe OmnigenicsAI’s products can play a pivotal role in revolutionizing health management. • Adoption: we anticipate that, as we enhance our customer experience and the industry develops, more consumers will desire genetic tests and physicians will be open and more willing to incorporate genetic information into their practice. This is especially true in encouraging adoption among non -geneticexperts, who are often the initial contact for customers and patients in a health journey. Further, we expect to advance adoption of our products and services by publishing research and providing educational support, thus generating awareness on the benefits of genetic testing. • Developing Strategic Partnerships: we are committed to commercializing our products through the Americas, developing a range of key partnerships with laboratories, providers, payers, among other market players. We will continue to bolster our existing partnerships while also exploring new ones to enter new markets and develop new products. These include diagnostic laboratories through a consortium, pharmaceutical companies, biopharma partners, healthcare service providers and health systems, who face significant barriers such as lack of technology, lack of localized genomic databases, and expertise. • Lower cost: as we plan on continuing to expand our business and network, we expect to reduce our costs while continuing our pursuit of accessible prices to further increase our addressable market. We are poised to benefit from the